For the first time, researchers tested CRISPR gene editing inside a person’s body. Allergan and Editas Medicine treated the first patient in the BRILLIANCE clinical trial of AGN-151587 at Oregon Health & Science University (OHSU) Casey Eye Institute. The therapy is being tested for treatment of Leber congenital amaurosis 10 (LCA10), an inherited type of blindness caused by mutations in the centrosomal protein 290 (CEP290) gene.

Novartis launched an external review into the safety of the company’s blindness medicine Beovu after the American Society of Retinal Specialists (ASRS) raised concerns.

Swiss pharma giant Roche’s 10-month journey to complete the acquisition of the gene therapy company Spark Therapeutics was finalized.

The Federal Trade Commission staff reviewing Roche’s plan to buy U.S.-based gene therapy specialist Spark Therapeutics for $4.3 billion recommended that the deal be approved without requiring any asset sales, the Capitol Forum reported.

Novartis received approval from the U.S. Food and Drug Administration for the Swiss pharmaceuticals company’s drug Beovu to treat a cause of vision loss.

Novartis AG’s gene therapy Luxturna for blindness is recommended for use on England’s public health service, according to the country’s healthcare cost-effectiveness watchdog NICE.

I got into Healthcare six years ago and canvassed major events to gain a consensus on what the future held.

A new study shows first-time proof that AI can detect the severity of diabetic macular edema, which is a leading cause of blindness.

Roche is buying U.S.-based gene therapy specialist Spark Therapeutics for $4.3 billion after developments in this area convinced the Swiss drugmaker to “step up”, Chief Executive Severin Schwan said.

ProQR Therapeutics N.V. announced that the company received Fast Track designation from the Food and Drug Administration for QR-421a for Usher syndrome type 2.